Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: ASIC and NGF/p75 antagonists - PainCeptor

Drug Profile

Research programme: ASIC and NGF/p75 antagonists - PainCeptor

Alternative Names: PPC-1807; PPC-5383; PPC-5692; PPC-778

Latest Information Update: 25 Oct 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PainCeptor Pharma Corporation
  • Class Small molecules
  • Mechanism of Action ASIC channel antagonists; Nerve growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 31 Dec 2009 Discontinued - Preclinical for Pain in Canada (unspecified route)
  • 15 Sep 2008 Preclinical development is ongoing
  • 24 Nov 2006 Preclinical data have been added to the adverse events and pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top